



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:	)	Appln. No.: 10/648,667
	)	Confirmation No.: 3920
CHENGJIN M. HUANG	)	Customer No.: 25291
	)	Group Art Unit: 1648
Filed: August 26, 2003	)	Examiner: Emily M. Le
	)	
For: MONOCLONAL ANTIBODY SPECIFIC FOR	)	
AN EPITOPE OF INACTIVATED FELINE IMMUNO-	)	
DEFICIENCY-ENCODED GLYCOPROTEIN	)	

TRANSMITTAL LETTER

Dear Sir:

Transmitted herewith for filing in the above-referenced patent application is an Amendment. No additional fee is required for this submission.

Thank you for your attention to this matter.

Respectfully submitted,

WYETH

Date: December 22, 2006

By: Anne M. Rosenblum  
 Anne M. Rosenblum  
 Attorney for Applicant  
 Registration No. 30,419

FILING BY EXPRESS MAIL UNDER 37 C.F.R. § 1.10

This correspondence and the accompanying documents identified hereinabove are being deposited with the U.S. Postal Service on December 22, 2006 to be delivered by the "Express Mail Post Office to Addressee" service under Mailing Label Number EQ 643041114 US addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Anne M. Rosenblum  
 Anne M. Rosenblum



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
(Attorney Docket No. AM101193)

<i>In re</i> Patent Application of:	)	Appln. No.: 10/648,667
	)	Confirmation No.: 3920
CHENGJIN M. HUANG	)	Customer No.: 25291
	)	Group Art Unit: 1648
Filed: August 26, 2003	)	Examiner: Emily M. Le
	)	
For: MONOCLONAL ANTIBODY SPECIFIC FOR	)	
AN EPITOPE OF INACTIVATED FELINE IMMUNO-	)	
DEFICIENCY-ENCODED GLYCOPROTEIN	)	

AMENDMENT

Dear Sir:

Responsive to the Office action of September 25, 2006, please amend the above-referenced patent application using the below instructions and consider the remarks in a positive light:

REMARKS

Reconsideration of this application, as amended, is respectfully requested. In accord with 37 C.F.R. § 1.121, the amendment and a listing of all claims in the application begin on a separate sheet. As required, only the claim number and status indicate the canceled claims. The amendment adds no new matter into the application. For the convenience of the Office staff, the amendment is placed in the below Appendix and incorporated herein by reference thereto.

The Examiner rejects Claims 1-10 and 19-21 under 35 U.S.C. § 112, second paragraph, asserting that the claims are indefinite for reasons given on pages 2-4 of the Office action.

With respect to the recitation "specific for an epitope unique to an inactivated FIV-encoded glycoprotein" being indefinite, Applicant disagrees with the Examiner's position. Without further comment, however, Applicant is amending Claim 1 and relevant dependent claims for the better readability thereof to advance prosecution towards an allowance.

Regarding the Examiner's concern of the use of the name of the monoclonal antibody "mAb 1D9" in Claims 7 and 21, it is explained that the name is not a trademark or a name used in trade. Rather, Applicant has coined the name for the particular monoclonal antibody "mAb 1D9" produced by the procedure demonstrated in the working examples of the present

Page 1 of 9